The antibody targets the toxic cargo itself, not the delivery address
Each year, more than 460,000 Americans are struck by Clostridioides difficile, a bacterial infection that exploits the very medicines meant to heal us, cycling through recurrence and leaving patients without a reliable way to break free. When the only approved antibody therapy was quietly discontinued in early 2025, it exposed how fragile our defenses against this pathogen had become. Now, a new monoclonal antibody called AZD5148 has demonstrated in animal models that it can protect against multiple strains of the bacterium at remarkably low doses — and through a mechanism that may prove more durable than what came before. Science, as it often does, has moved to fill the void left by commerce.
- The January 2025 discontinuation of bezlotoxumab stripped clinicians of their only FDA-approved antibody tool against C. difficile recurrence, leaving a dangerous gap in care for the most vulnerable patients.
- AZD5148 neutralizes the toxin's destructive cargo before it can be delivered inside host cells — a fundamentally different strategy that may outmaneuver the genetic diversity of circulating bacterial strains.
- In mouse trials, AZD5148 achieved 90 percent survival against a virulent strain at doses where bezlotoxumab protected only 20 percent, signaling a potentially significant leap in potency.
- Even against the one toxin variant it could not neutralize in laboratory conditions, AZD5148 still reduced tissue damage in living animals — suggesting its protective reach is broader than test-tube results alone can measure.
- Phase I clinical trials are now underway, racing to translate these preclinical findings into a viable therapy as C. difficile spreads increasingly beyond hospitals and into communities.
Clostridioides difficile has become the leading cause of antibiotic-associated intestinal infection in the United States, responsible for over 462,000 cases and nearly 13,000 deaths in a single year. The infection is cruelly self-reinforcing: the antibiotics used to treat it deepen the gut disruption that allows it to return, trapping patients in cycles of recurrence. Two large protein toxins — TcdA and TcdB — do the cellular damage, and for years the field's best answer was bezlotoxumab, a monoclonal antibody approved in 2018 to blunt that cycle in high-risk patients. When its manufacturer discontinued the drug in January 2025, clinicians were left without any approved antibody therapy.
Into that void comes AZD5148, a newer antibody that researchers have now tested in mouse models with striking results. Where bezlotoxumab worked by blocking TcdB from attaching to cell-surface receptors, AZD5148 targets the toxin's glucosyltransferase domain — the destructive payload itself — and prevents it from being delivered into the cell interior. Because C. difficile strains produce three major TcdB variants that differ in which receptors and intracellular targets they engage, this downstream approach may offer broader coverage across the pathogen's genetic diversity.
In laboratory neutralization assays, AZD5148 outperformed bezlotoxumab against the two most common variants by factors of roughly 1,000 and 14,000 respectively. The mouse studies were equally compelling: against an epidemic strain, AZD5148 protected animals at doses as low as 0.1 mg/kg, with treated mice losing far less body weight than untreated controls. Against a highly virulent strain, AZD5148 achieved 90 percent survival at a dose where bezlotoxumab managed only 20 percent.
Perhaps the most unexpected finding involved the third toxin variant, TcdB3, which AZD5148 failed to neutralize in vitro. Yet in infected mice, the antibody still reduced tissue inflammation and cellular damage — a result that suggests its protective action in living systems extends beyond simple toxin blockade. The binding site AZD5148 targets differs by only a single amino acid across all three variants, which may underlie this broader-than-expected effect. With Phase I clinical trials now beginning, AZD5148 arrives not merely as a substitute for what was lost, but as a potentially more capable successor.
Clostridioides difficile has become the leading cause of antibiotic-associated intestinal infections in the United States, with 462,100 cases and 12,800 deaths reported in 2017 alone. The infection spreads through spores that exploit the disrupted gut microbiome left behind by antibiotics, germinating in the colon and producing two large protein toxins—TcdA and TcdB—that destroy intestinal cells and trigger severe inflammation. Standard treatments like vancomycin and fidaxomicin kill the bacteria but perpetuate the very dysbiosis that allows the infection to recur, leaving patients vulnerable to repeated bouts of disease.
For years, the field had pinned hopes on bezlotoxumab, a monoclonal antibody that neutralized the TcdB toxin and was approved by the FDA in 2018 to prevent recurrence in high-risk patients. But in January 2025, its manufacturer discontinued production, leaving clinicians without an approved antibody therapy and patients without a proven option to break the cycle of reinfection. That gap may soon close. Researchers have now demonstrated that a newer antibody called AZD5148 offers superior protection against diverse strains of C. difficile in mouse models, working through a fundamentally different mechanism than its predecessor.
The key difference lies in how the two antibodies attack the toxin. Bezlotoxumab binds to a region of TcdB called the CROPS domain, blocking the toxin from attaching to receptors on the surface of host cells. AZD5148 takes a different approach: it targets the glucosyltransferase domain, the toxic cargo itself, and prevents it from being delivered into the cell's interior where it causes damage. This downstream mechanism matters because C. difficile strains produce three major variants of TcdB that differ in which cellular receptors they recognize and which proteins they attack inside the cell. By targeting the cargo rather than the delivery address, AZD5148 potentially sidesteps these variant-specific differences.
In laboratory tests using purified toxins, AZD5148 neutralized the two most common variants—TcdB1 and TcdB2—with remarkable potency, roughly 1,000 times more effective than bezlotoxumab against TcdB1 and 14,000 times more effective against TcdB2. Against the third variant, TcdB3, AZD5148 showed no neutralizing activity in vitro, while bezlotoxumab retained some effect. But the mouse studies revealed something unexpected. When researchers infected mice with the epidemic R20291 strain, which produces TcdB2, AZD5148 protected animals at doses as low as 0.1 milligrams per kilogram—far lower than the doses of bezlotoxumab required for the same protection. Treated mice lost only 5 to 10 percent of their body weight compared to 18 percent in untreated controls, and survival improved significantly across all doses tested.
The advantage held against a highly virulent TcdB1-producing strain called VPI 10463. At a dose of 2.5 milligrams per kilogram, AZD5148 achieved 90 percent survival while bezlotoxumab protected only 20 percent of mice. Even at a higher dose of 10 milligrams per kilogram, bezlotoxumab managed only 40 percent survival while AZD5148 achieved complete protection. The most striking finding came with the TcdB3-producing M68 strain. Despite failing to neutralize TcdB3 in the laboratory, AZD5148 still reduced tissue swelling and inflammatory cell infiltration in infected mice, suggesting that the antibody's protective mechanism in living animals involves more than simple toxin neutralization. The epitope where AZD5148 binds is nearly identical across all three TcdB variants, differing by only a single amino acid, which may explain why the antibody can still exert protection even when it cannot block toxin activity in a test tube.
These preclinical results arrive at a moment of clinical urgency. C. difficile infection has shifted from a primarily hospital-acquired problem to one affecting communities, with half of all cases now occurring outside healthcare facilities. The emergence of new epidemic strains and the genetic diversity of the toxins they produce have made treatment increasingly complex. With bezlotoxumab gone and no approved alternative available, patients and physicians have been left without a proven antibody-based option. AZD5148 is now entering Phase I clinical trials to assess safety, tolerability, and pharmacokinetics in healthy adults, with the potential to fill a critical gap in the therapeutic arsenal. The antibody's ability to protect against multiple toxin variants at lower doses than its predecessor suggests it could offer a meaningful advance—not just a replacement, but an improvement.
Citas Notables
AZD5148 provides superior protection in a mouse model of CDI caused by diverse C. difficile strains. By blocking the delivery of toxic cargo into the cell, AZD5148 efficacy is independent of the receptor tropism differences observed across TcdB subtypes.— Study authors, PLOS Pathogens
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that AZD5148 targets the toxin's cargo rather than its delivery address?
Because C. difficile doesn't stand still. The bacterium produces three major variants of TcdB that recognize different receptors on host cells. Bezlotoxumab works by blocking the receptor-binding domain, so when the toxin's target receptors change, the antibody becomes less effective. AZD5148 targets the toxic enzyme itself—the part that actually damages cells. That part is nearly identical across all variants. It's like the difference between stopping a package at the mailbox versus stopping it at the door—one approach depends on the address, the other doesn't.
The lab tests showed AZD5148 couldn't neutralize TcdB3 at all. How did it still protect mice?
That's the puzzle that made this work interesting. The epitope—the spot where AZD5148 binds—differs by only one amino acid between TcdB3 and the other variants. In a test tube with purified toxin and cells, that single difference was enough to break the antibody's grip. But in a living mouse, something else was happening. The antibody still reduced swelling and inflammatory cell infiltration even though it couldn't block the toxin's activity in vitro. It suggests the protection involves more than just neutralization—perhaps the antibody helps the immune system clear the toxin, or the tissue damage itself creates conditions where even imperfect binding helps.
Why was bezlotoxumab discontinued if it was FDA-approved?
The company that made it decided to stop production in January 2025. The reasons aren't entirely clear from the science alone, but it left a real gap. Bezlotoxumab worked—it reduced recurrence in high-risk patients. But it wasn't perfect, and it required higher doses for some strains. When a company exits a market, it's usually a business decision, not a scientific one. The clinical need didn't disappear.
These are mouse studies. What's the leap to humans?
It's substantial but not unprecedented. The mouse model of C. difficile infection has historically predicted human outcomes—bezlotoxumab's efficacy in mice correlated with its real-world effectiveness in patients. But mice aren't people. Their immune systems work differently, their gut microbiomes are different, and the infection behaves differently. AZD5148 is now in Phase I trials, which will tell us whether it's safe and how long it stays in the bloodstream. That's the first step. Efficacy in humans will take longer to establish.
What happens if AZD5148 works in humans?
It could change how we approach C. difficile, especially recurrence. Right now, antibiotics are the standard treatment, but they're part of the problem—they wipe out the protective bacteria that normally keep C. difficile in check. An antibody that neutralizes the toxin without killing the microbiome could be given alongside antibiotics or even after them, to prevent the recurrence that happens in 20 to 30 percent of patients. For high-risk groups—the elderly, the immunocompromised, those with severe disease—it could be genuinely life-changing.